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ABSTRACT
Background: Hepatitis C is a global health concern that represents a major cause of 
liver disease and socioeconomic burden. Currently, there is no vaccine that protects 
against this infection or drug that treats it eﬀectively. The current treatment for hepa-
titis C virus (HCV) infection does not produce a sustained virologic response. There-
fore, discovery and identiﬁcation of a new drug for HCV treatment is a high priority. 
Camel milk is a traditional medicine that could improve the control of HCV.
Objectives: To assess the potential eﬀect of casein puriﬁed from camel milk on HCV cel-
lular infectivity in a tissue culture model.
Materials and Methods: Casein was puriﬁed from defatted camel milk to electrophoretic 
homogeneity. PBMCs and HepG2 and HeLa cell lines were used. Three kinds of experi-
ments were conducted. HCV was directly interacted with casein and then mixed with 
diﬀerent cell types, casein was incubated with the cells and then exposed to HCV, and 
the HCV pre-infected cells were treated with casein at diﬀerent concentrations and 
time intervals. Non-infected cells were used to assess cytotoxicity and the apoptosis 
eﬀect of casein.
Results:Direct interaction of casein (with or without α-lactalbumin) with neither the 
virus nor the cells prevented HCV cell entry. However, casein with α-lactalbumin in-
duced a cytotoxic eﬀect in HepG2 and HeLa cell lines but not in human naïve leuko-
cytes. At all concentrations tested, casein with α-lactalbumin could induce apoptosis 
in both infected and non-infected HepG2 cells.
Conclusions: Camel milk casein (with or without α-lactalbumin) did not demonstrate 
any anti-HCV activity. However, the cellular apoptotic cascade was initiated in HepG2 
and HeLa cells treated with casein (with α-lactalbumin) but not in naïve leukocytes.
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1. Background
Globally, over 170 million people are infected with the 
hepatitis C virus (HCV), and the devastating impact of 
this virus is further magniﬁed by the high frequency of Hepat Mon. 2011;11(9):724-730
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3.2. Protein and Endotoxin Determination
Protein content was determined by directly measuring 
the absorbance at 280 nm with the Bradford method (8), 
using bovine serum albumin as the standard protein. The 
endotoxin level in the casein was checked (9) to avoid its 
pyrogenic eﬀects on the cell-culture system. All casein 
batches used were free of endotoxin (data not shown).
3.3. Sodium Dodecyl Sulfate-Polyacrylamide Gel Elec-
trophoresis (SDS-PAGE)
To examine the homogeneity and molecular weight of 
puriﬁed casein, it was subjected to electrophoresis under 
reducing conditions with the use of a 12% SDS polyacryl-
amide gel. The gel was stained and destained according 
to previous standard protocols (10).
3.4. Infected Serum Samples
For all infection experiments, PCR-HCV positive serum 
samples of genotype 4a from Egyptian patient “A.R.” (af-
ter approval by the ethics committee) were used as previ-
ously described by Redwan and Tabll (5).
3.5. Cytotoxicity of Casein 
The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazo-
lium bromide (MTT) assay is a simple non-radioactive 
colorimetric assay for measuring cell cytotoxicity, pro-
liferation or viability (5, 11, 12) In brief, peripheral blood 
mononuclear cells (PBMCs) were isolated (5), about 104 
PBMCs and HepG2 cells in 150 µL complete media (5% 
fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyru-
vate, 100 µg/mL penicillin-streptomycin, and 50 µg/mL 
gentamycin, and 50 µM 2-mercaptoethanol) were plated 
per well in a 96-well plate. After incubation (37 oC, 5% CO2) 
overnight, the cells were treated with camel casein (2 
mg/mL) for 4 and 8 days. The cells were washed 3 times 
with 200 µL PBS, and 200 µL MTT solution (0.5 mg/mL in 
PBS) was added to each well. After further incubation (37 
oC, 5% CO2) for 3–4 h, the medium was discarded, and the 
wells were dried. Formazan crystals were resuspended in 
200 µL dimethyl sulfoxide, followed by shaking for 5 min 
to thoroughly mix the formazan into the solvent. The op-
tical density was read at 550 nm. The relative cell viability 
(%) compared to control wells containing cell culture me-
dium without casein was calculated using the following 
formula: (A) test/(A) control × 100%.
3.6. Inhibitory Potential of the Casein on HCV
To examine the interaction of casein with human PB-
MCs (2.5 × 105) and HepG2 cells, 105 cells were plated in 
two 24-well microtiter plates. Casein (free or containing 
α-lactalbumin) was added to the leukocytes and HepG2 
cells (in 50 mL of RPMI-1640-supplemented medium) at a 
ﬁnal concentration of 2.0 mg/mL for each type of cell and 
incubated for 60 min at 37ºC. Free casein was removed by 
washing 3 times with 1 mL PBS. After adding 1 mL of 2% 
HCV persistence during infection, i.e. a chronic infection 
results in up to 85% of cases. HCV infection has become 
the most common cause of hepatocellular carcinoma 
and the primary reason for liver transplantations among 
adults in the Western world (1). Egypt has the highest 
number (12%) of HCV-infected patients and consequently 
a larger portion of its population is at risk of infection 
(2, 3). In Egypt, The majority of HCV-infected patients are 
concentrated in villages and terminal urban and central 
cities where income rates range from low to very low. 
Interferon-α2a remains the drug-of-choice, despite its 
low eﬃcacy and adverse side eﬀects (4). Combination 
therapy using pegylated IFN-α2a and ribavirin improves 
the response rate to around 60% with fewer side eﬀects 
(4), but still the economical factors standard special at 
developing countries.
Camel’s milk is an important nutritional source in sev-
eral world regions, and it is consumed fresh or curdled. 
Often, HCV-infected Egyptian patients consume large 
amounts of camel’s milk as an alternative and/or sup-
portive medicine (5). To explore the macromolecules 
in camel’s milk that may be responsible for its protec-
tive potential, we previously screened and analyzed the 
potential anti-HCV activity of 2 camel milk proteins: 
lactoferrin and amylase. Lactoferrin showed signiﬁcant 
activity against HCV cell entry into both human naïve 
leukocytes and HepG2 cells, while amylase failed to exert 
any anti-viral activity in the same tissue culture system. 
These studies did not ﬁnd any cytotoxic eﬀect for camel 
milk lactoferrin or amylase on naïve leukocytes or HepG2 
cells (5-7). Both lactoferrin and amylase represent minor 
proteins in camel milk. However, camel casein accounts 
for 80% (v/v) of the whole protein inventory, which can be 
simply isolated from skimmed milk by lowering the pH.
2. Objectives
The current investigation focused on exploring the an-
ti-HCV potential activity of puriﬁed camel milk casein on 
both naïve leukocytes and HepG2 cells.
3. Materials and Methods
3.1. Processing of Camel Milk and Casein Puriﬁcation
Milk from camels (Camelus dromedarius) was pur-
chased from ALKHIR camel farm (Giza, Egypt) and trans-
ferred frozen to our laboratory. A solution of sodium 
azide (0.2%) containing 5 mM EDTA and 5 mM PMSF was 
added to the milk before defatting by centrifugation at 
1000 × g for 30 min at 4 oC. The pH of skimmed milk was 
decreased to 4.6 with 1 M HCl to precipitate the casein. Af-
ter centrifugation at 5000 × g for 15 min, the casein pellet 
was separated from the whey supernatant and washed 
2 times with cold distilled water, then further puriﬁed 
by readjusting its pH twice to exclude α–lactalbumin, 
which yielded casein-free α-lactalbumin (casein without 
α-lactalbumin), and then lyophilized.Hepat Mon. 2011;11(9):724-730
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HCV-infected serum (8.3 × 106 copies/mL, genotype 4a) 
to each well, the cells were incubated for 90 min at 37ºC, 
then washed 3 times and cultured for 7 days at 37ºC. To ex-
amine the interaction of casein with HCV, 1 mL of infect-
ed serum and casein (at a ﬁnal concentration of 2.0 mg/
mL) was pre-incubated in 50 mL of medium for 1 h at 4ºC. 
Then, the mixture of HCV and casein was added to leu-
kocytes or HepG2 cells cultured as described above and 
then incubated for 90 min at 37 ºC. However, the treat-
ability of casein was examined as follows. Pre-infected 
cells were exposed to puriﬁed casein with and without 
α-lactalbumin at concentrations of 0.25, 0.5, 0.75, 1.0, and 
2.0 mg/mL after 4 and 8 days from infection, respectively. 
The negative control was infected cells cultured without 
treatment. The cells were washed 3 times with 1 mL of me-
dium and further cultured for 7 days at 37 ºC, followed by 
total RNA extraction (5).
3.7. Intracellular HCV Immunostaining Assay
The intracellular HCV immunostaining assay was per-
formed in a 24-well microtiter plate. Casein (2 mg/mL) was 
incubated with infected serum for 1 h at 4 ºC, and then the 
mixture of HCV and casein was added to cells cultured as 
described above and incubated for 90 min at 37 ºC. The 
cells were washed 3 times with 1 mL medium and further 
cultured for 7 days at 37 ºC. On day 8, blocking buﬀer (2% 
bovine serum albumin or gelatin in PBS) was added and 
left for 1 h at room temperature. Then, the cells were ﬁxed 
with paraformaldehyde and permeabilized with 0.5% 
Triton-X100. Puriﬁed primary antibody (11, 13) diluted to 
1:2000 was then added, followed by incubation for 1 h at 
room temperature. Horseradish peroxidase-conjugated 
anti-human IgG (diluted 1:2000 with 2% bovine serum al-
bumin or gelatin-PBS) were added to the cell monolayer 
and incubated for 1 h at room temperature. The reaction 
was developed with 3, 3′-diaminobenzidine (DAB)-perox-
idase substrate and stopped after 10 min of incubation 
with distilled water. Positive and negative controls were 
included. The distinct colored foci were examined, and 
some positive and negative ﬁelds were pictured by using 
a phase contrast microscope Olympus 1X70 (Olympus op-
tical, Tokyo, Japan).
3.8. Extraction and PCR of Genomic and Anti-genomic 
RNA Strands of HCV
Strands of HCV RNA were isolated from PBMCs and 
HepG2 cells as previously described (3, 5). Reverse 
transcription-nested PCR was carried out as previously 
reported (5, 7). Retrotranscription was performed in 
a 25 µL reaction mixture containing 20 U of AMV re-
verse transcriptase (Clontech) with either 400 ng of 
total RNA of HepG2 cells or PBMCs, 40 U of RNAsin 
(Clontech), a ﬁnal concentration of 0.2 mmol/L of each 
dNTP (Promega, Madison), and 50 pmoL of the reverse 
primer 1CH: 5′-GGTGCACGGTCTACGAGACCTC-3′ (for the 
plus strand) or 50 pmol of the forward primer 2CH: 5′-
AACTACTGTCTTCACGCAGAA-3′ (for the minus strand). 
The reaction mixture was incubated at 42ºC for 60 min 
and denatured at 98 for 10 min. The highly conserved 
5′-UTR sequences was ampliﬁed using 2 rounds of PCR 
with 2 pairs of nested primers. First-round ampliﬁca-
tion was performed in a 50µL reaction mixture con-
taining 50 pmol each of 2CH forward primer and P2: 
5′-TGCTCATGGTGCACGGTCTA-3′ (reverse primer), 0.2 
mmol/L of each dNTP, 10 µL from RT reaction mixture 
as template and 2 U of Taq DNA polymerase (Promega) 
in a 1 × buﬀer supplied with the enzyme. The thermal 
cycling protocol was as follows: 1 min at 94ºC, 1 min at 
55ºC, and 1 min at 72ºC for 30 cycles. The second-round 
ampliﬁcation was done similar to the ﬁrst-round, ex-
cept for the use of the nested reverse primer D2: 5′-
ACTCGGCTAGCAG TCTCGCG-3′ and forward primer F2: 
5′-GTGCAGCCTCCAGGACCC-3′ at 50 pmol each. A 174 bp 
fragment was identiﬁed in the positive samples.
3.9. Apoptosis Assessment
3.9.1. DNA Fragmentation Assay
Cells were harvested after 8 days of casein treatment, 
washed with cold PBS, and then the oligonucleosome 
length DNA fragments in the samples were detected by 
agarose gel electrophoresis (14). In brief, the cells were 
suspended and centrifuged, then lysed in 5 mM Tris, con-
taining 20 mM EDTA, 0.5% Triton-X100, pH 8.0 at 4oC over-
night and centrifuged at 16000 × g for 20 min. DNA oligo-
somes in the supernatant were precipitated with ethanol 
overnight at –20oC, treated with proteinase K (50 µg/mL) 
and RNase (50 µg/mL), and then loaded on 1.8% agarose 
gel. The samples were electrophoresed at a constant volt-
age 100 V for 60 min. The gel was stained with ethidium 
bromide and then visualized and photographed on the 
UV transilluminator of a gel documentation system.
3.9.2. Acridine Orange/Ethidium Bromide (EB/AO) Stain-
ing Assay
The dye mix of EB/AO consisted of 100 µg/mL ethidium 
bromide and 100 µg/mL acridine orange in PBS. The treat-
ed cells (PBMCS and HepG2) were stained with EB/AO. The 
EB/AO dye mix (8 µL) was added to each well, and the cells 
were viewed and counted after 15 min with an Olympus 
1X70 (Olympus, Japan) inverted microscope at 40x mag-
niﬁcation with an excitation ﬁlter (480/30nm), a dichro-
matic mirror cut-on 505 nm LP. Pictures were taken with 
an Olympus microscope equipped with a digital camera. 
All tests were done in triplicate. A minimum of 100 cells 
were counted.
4. Results
4.1. Puriﬁcation of Camel Casein
Ten liters of Arabian camel milk was defatted. Casein 
was isolated from the acidiﬁed defatted milk, which 
yielded 4 and then 3 bands in SDS-PAGE after repuriﬁca-Hepat Mon. 2011;11(9):724-730
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4.3. Eﬀect of Camel Casein on Intracellular Replication of 
HCV
Camel casein with and without α-lactalbumin at con-
centrations of 0.25, 0.5, 0.75, 1.0, and 2.0 mg/mL was in-
vestigated for its ability to inhibit viral replication inside 
infected PBMC and HepG2 cells in vitro (data not shown). 
tion. The molecular mass of camel casein was estimated 
to be 27.7, 24.9, and 22.0 kDa and that of α-lactalbumin 
was estimated to be 14.4 kDa (Figure I).
4.2. Inhibition Potential of Camel Casein
Camel casein without α-lactalbumin could not block 
HCV cell entry. One set of cells, PBMCs (2.5 × 105) or HepG2 
cells (105), was cultured in duplicate, as described under 
Materials and Methods. One of the cultures was treated 
with 2.0 mg/mL casein for 60 min and then infected with 
HCV for 90 min. Camel casein could not protect the cells 
from HCV entry (Figure 2). The other cultures were inocu-
lated with HCV-infected sera pretreated with casein (2.0 
mg/mL) for 60 min. The inoculated cells were cultured 
for 8 days. In these cells, RT-nested PCR ampliﬁed a 174 bp 
region at the 5′ end of the HCV non-coding sequence in 
comparison to the positive control (cells infected with 
HCV) and negative controls (cells without infection). 
The 174-bp band was not detected in case of HepG2 cells, 
while it was detected in the case of PBMCs (Figure 2).
Figure 3. (I) Typical Pictures of HCV-Infected (A) PBMCs and (B) HepG2 cells 
under a light microscope (40x). Pictures A1 and B1 are the negative control. 
Pictures A2 and B2 are HCV-infected cells treated with camel casein for 4 days. 
Pictures A3 and B3 are HCV-infected cells treated with camel casein for 8 days. 
The arrows indicate the foci. (II) A panel indicates naïve human PBMCs and 
cells treated with casein (containing α-lactalbumin) at concentrations of 0.5 
and 2.0 mg/mL (a, b, and c, respectively) for 8 days. Both naïve and treated 
cells were healthy. The panel below demonstrates the symptoms of apopto-
sis in HepG2 cells, which were visualized using the EB/AO method. Untreated 
HepG2 cells (a), and HepG2 cells were treated with 2.0 mg/mL camel casein 
for 4 days (b) and 8 days (c). (N) indicates necrotic cells; (A) indicates bright 
orange apoptotic cells. Normal green cells indicate non-apoptotic cells. (III) 
A panel showing the pictures of (A1-3) HepG2 cells, (B1-3) HeLa cells, and (C1-3) 
PBMCs under a light microscope (×20). Pictures A1, B1, and C1 show untreated 
cells. Pictures A2, B2, and C2 show cells treated with 0.5 mg/mL camel casein, 
and pictures A3, B3, and C3 show cells treated with 2.0 mg/mL casein. Camel 
casein did not exert any eﬀect on PBMCs but exhibited typical apoptotic ac-
tivity against HepG2 and HeLa cells.
(I)
(II)
(III)
Figure  1. (A) 12% SDS-Urea PAGE of Casein Puriﬁed from Camel Milk. Four bands: 
3 with molecular weights of 27.7, 24.9, 22.0 kDa, and α-lactalbumin with a mo-
lecular weight of 14.4 kDa. Lane 1 is repuriﬁed casein without α-lactalbumin, 
and lane 2 is puriﬁed casein with α-lactalbumin. (B) The agarose gel picture 
reveals the eﬀect of camel casein on HepG2 and HeLa cells (II and III, respect-
ively). The apoptotic DNA nucleosomes were run in 1.8% agarose gel after 8 
days of casein (with α-lactalbumin) treatment. Lane 1 was the negative control 
(untreated cells). Lane 2 was the positive control (cells treated with the apop-
tosis inducer H2O2). Lane 3 was cells treated with 0.5 mg/mL casein, and lane 
4 was cells treated with 2.0 mg/mL casein. DNA fragmentation was visualized 
with ethidium bromide as described in Materials and Methods.
Figure 2. Camel Casein Activity against HCV. Lane 1 is the DNA ladder, lanes 2 
and 5 are negative control samples for HepG2 cells, and lanes 3 and 6 are posi-
tive control samples for HepG2 cells. Casein with and without α-lactalbumin at 
a concentration of 2.0 mg/mL was tested for its ability to block HCV entry into 
HepG2 cells (lanes 4 and 7, respectively). Lanes 8 and 9 are the negative and 
positive control samples for PBMCs, respectively, and casein at a concentration 
of 2.0 mg/mL was tested for its ability to block HCV entry into PBMCs (lane 10). 
Ampliﬁed products were resolved in 3% agarose gel, followed by ethidium bro-
mide staining.Hepat Mon. 2011;11(9):724-730
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Inhibition of viral replication was detected by amplifying 
viral RNA segments, using RT-PCR. Casein could not inhib-
it HCV replication at concentrations of 0.25, 0.5, 0.75, 1.0, 
and 2.0 mg/mL after both ﬁrst (4 days) and second doses 
(8 days) of treatment in both cell types. In case of casein 
with α-lactalbumin, the 174-bp band was not detected in 
HepG2 cells in case of casein with α-lactalbumin, while it 
was detected in PBMCs (data not shown). The diﬀerential 
appearance of the 174-bp band may be due to the reduced 
viability in HepG2 cells only.
4.4. Assay of HCV Immunostaining in PBMC and HepG2 
Cells
Immunostaining assays have been widely used to eval-
uate the neutralizing antibody responses to viruses that 
can form foci in infected cells. After 8 days of infection 
and cell permeabilization, detection of the HCV foci was 
carried out using primary antibody and a peroxidase an-
ti-human IgG probe. The reaction was developed with 3, 
3′ diaminobenzidine (DAB) horseradish peroxidase sub-
strate. The viral foci were stained brown, rendering them 
easily visualized under the light microscope. Figure 3 I 
demonstrates that the viral foci were clearly detected in 
PBMCs, while in HepG2 cells, the cell membrane did not 
appear to be ﬁrm, which might indicate apoptosis.
4.5. Cytotoxic Eﬀect of Camel Casein
To rule out the possibility that the elimination of the 
HCV was caused by the reduced viability of PBMCs or 
HepG2 cells, the cytotoxic eﬀects of camel casein (with 
Figure 4. Viability of PBMCs (I) and HepG2 Cells (II) Treated with Camel Casein 
Containing α-Lactalbumin for 4 and 8 Days. Cell Viability was Examined by the 
MTT Assay, and the Data Presented are the mean ± standard Deviation of the 
Assays Conducted in Triplicate.
α-lactalbumin) on the cells were examined. PBMCs (104) 
and HepG2 cells (104) were treated with camel casein (2 
mg/mL) for 4 and 8 days, respectively. Cell viability was 
compared with that of untreated PBMCs and HepG2 cells. 
Casein had no adverse eﬀects on the viability of PBMCs 
after incubation for 4 and 8 days. In the case of HepG2 
cells, viability was reduced to 30% after 4 days of incuba-
tion and to 3% after 8 days of incubation (Figure 4). Micro-
scopic examination revealed instability in both HepG2 
and HeLa cell membranes, ranging from an unorganized 
to a destructive appearance (Figure 3 II, III). In contrast, 
casein (without α-lactalbumin) did not exert toxic eﬀects 
on both cell lines (data not shown).
4.6. Camel Casein Induces Apoptosis in HepG2 and 
HeLa Cell Lines
The cytotoxic eﬀect of casein containing α-lactalbumin 
on the cancer cell lines prompted us to examine casein’s 
apoptotic eﬀect in comparison with its eﬀect without 
α-lactalbumin. To check the ability of puriﬁed camel casein 
to initiate the apoptosis cascade in HepG2 and HeLa cells 
and PBMC cells, 0.5 and 2.0 mg/mL of puriﬁed casein were 
incubated with these cells for 4 and 8 days. We screened 
for apoptotic events using DNA fragmentation (DNA 
leader) and EB/AO staining and microscopic examination. 
Typical DNA laddering was clearly induced in HepG2 and 
HeLa cells (Figures 3 I, II, and III) at both concentrations of 
casein used (results for 0.5 mg are presented) but was ab-
sent in treated PBMC and untreated HepG2 cells. However, 
EB/AO staining results indicated DNA fragmentation. By 
using these methods, we determined the live and apop-
totic cells in both suspension cells (PBMCs) and adherent 
cells (HepG2 and HeLa). The results indicated that casein 
had no eﬀect on PBMC cells (Figure 4 I) at concentrations 
of 0.5 and 2.0 mg/mL, while it induced apoptosis in HepG2 
and HeLa cells (Figure 4 II). Live cells showed normal green 
nuclei; early apoptotic cells exhibited bright green nuclei 
with condensed or fragmented chromatin; and late apop-
totic cells displayed condensed and fragmented orange 
chromatin. A comparison of the eﬀect of camel casein at 
concentrations 0.5 and 2.0 mg/mL on untreated and treat-
ed PBMCs, HepG2, and HeLa cells is presented in Figure 4 II.
5. Discussion
Numerous studies have shown that HCV genotype-4 pa-
tients have a response rate to interferon-α (IFN-α) mono-
therapy or combination therapy with ribavirin (RBV) 
that is less favorable than that of genotypes 2 and 3; and 
HCV genotype-4 patients have a response failure rate of 
approximately 60%. Resistance to antiviral therapy re-
mains a serious problem in the management of chronic 
hepatitis C; thus, there is an urgent need for a novel in-
terferon or drugs (4, 15-17). Several types of traditional 
medicines have been used by HCV patients in Egypt as 
supportive and/or adjuvant treatment, with camel milk 
being the most popular among these. Our previous ex-
amination of 3 camel milk proteins, namely, lactoferrin, Hepat Mon. 2011;11(9):724-730
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amylase, and immunoglobulin G (IgGs), revealed that 
they had anti-HCV activity ranging from undetectable 
(amylase) to intermediate (IgGs) to strong (lactoferrin) 
(5-7, 11). In this study, we investigated the potential activ-
ity of camel casein against hepatitis C virus infectivity in 
HepG2 and PBMCs. Results show that camel casein failed 
to inhibit HCV entry into PBMCs and HepG2 cells, either 
by direct interaction with virus molecules or interaction 
with cells. HCV was eliminated by the reduced viability 
of HepG2 cells because camel casein induced apoptosis 
in and reduced the viability of HepG2 tumor cells. Conse-
quently, HCV RNA was not detected when casein was used 
as the treatment, regardless of the casein concentration.
Casein represents the main protein in milk. It is not 
present in milk as a single element; instead, it forms a 
large complex with calcium phosphate (18). Casein con-
sists of acidic proteins with pIs ranging between pH 4.9 
and 5.9 and molecular weights ranging between 19 and 
28 kDa. Although hitherto no biological activity has been 
ascertained for casein, it is nevertheless considered an 
important nutritional component, i.e., a source of bioac-
tive peptides. No antiviral activity has been ascribed to 
intact casein (19), as in the current work. However, chemi-
cally modiﬁed caseins may acquire antiviral properties. 
In fact, a large number of bioactive peptides derived 
from the proteolytic hydrolysis of casein have been iso-
lated and characterized. These peptides perform several 
biological activities such as antimicrobial (20), opioid 
agonistic and antagonistic (21), immunomodulatory 
(22), mineral-binding (23), antihypertensive (24) and an-
tithrombotic (25) activities.
The unexpected results we obtained were due to the 
cytotoxic eﬀects of casein. The above mentioned results 
indicate that the α-lactalbumin in puriﬁed camel casein 
may represent the factor responsible for the current 
apoptosis induction in both HepG2 and HeLa cell lines. 
The present results are in agreement with those of Svens-
son et al. (26) who reported that upon unfolding, human 
and bovine α-lactalbumin can form a tumoricidal com-
plex with oleic acid called human alpha-lactalbumin, 
which is lethal for tumor cells (HAMLET). This complex 
induces diﬀerential and signiﬁcant apoptosis in several 
cancer lines (14, 27, 28). Camel casein was not able to 
block or neutralize HCV cell entry either by direct or indi-
rect interaction. However, casein could induce the apop-
tosis cascade in both HepG2 and HeLa cells.
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